Cambridge, UK, 25 November 2024: Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.
A renowned leader in the…
Pioneer Group has today announced a collaboration agreement with Thermo Fisher Scientific to support biotech founders on their journey towards commercialising intellectual property in the healthcare and sustainability sectors.
Through the collaboration, biotech startups based at Pioneer sites across the UK and Ireland, including its new landmark life sciences location at Victoria House in London in partnership with Oxford Properties, will receive access to training, events, technical support, bespoke equipment, and consumables from Thermo Fisher. In addition, companies that graduate from…
We are delighted to invite our network to attend our upcoming roundtable breakfast in collaboration with Cambridgeshire Chambers of Commerce.
Have a look at our exclusive invitation here and submit your registrations! Limited spaces available...
AMSBIO has implemented a program of investment to support the students at Penn State Lehigh Valley, part of Pennsylvania State University, in their transformative Course-based Undergraduate Research Experience (CURE) program.
The CURE program, led by Dr. Jacqueline McLaughlin, allows students to dive into real-world research projects that tackle critical challenges in health and medicine. This semester’s focus is on exploring the endothelial glycocalyx—a sugar-rich layer vital for cardiovascular health.
In this project, students analysed how various basement…
The European Partnership for Personalised Medicine introduces two exciting opportunities for start-ups, researchers, and early-stage teams working on cutting-edge solutions in personalized medicine. These programmes aim to accelerate the development, validation, and market readiness of transformative innovations that enhance patient care.
Fast Track Validation Programme
Designed to address a critical bottleneck in personalized medicine development, this programme supports validation studies to elevate projects to higher technological and market readiness levels.
Who Can Apply? …
Read eNews for December here. Featuring:
✅ Tony Jones, CEO, One Nucleus - Tis the Season to be Jolly!✅ Key Dates for Your 2025 Diary by Alicia Gailliez, Business Development Manager, One Nucleus✅ Reflections on Genesis 2024✅ One Nucleus Engagement in JPM Week 2025 by Tony Jones, One Nucleus✅ Memes Meet Microbes: Spreading Awareness About Antimicrobial Resistance by CSIRO✅ A Decade of Innovation, a Decade to Come - China’s Biopharmaceutical Innovation by Clarivate
Inaphaea BioLabs, the translational contract research organisation based at MediCity Nottingham, has announced the promotion of Melissa Barr to Head of Scientific Operations.
Melissa joined Inaphaea in 2023 as Lead Scientist. Since then, she has played an instrumental role in delivering preclinical drug discovery projects across oncology and women’s health, as well as leading a team of scientists on-site.
Spun out from ValiRx PLC, Inaphaea offers cell-based assays specialising in oncology. Its aim is to improve the translation of early drug discovery projects towards the clinic.
Commenting…
A lack of access to capital, particularly proof-of-concept funding, is stifling growth in the UK’s university spinout sector, according to a recent survey conducted by Symbiosis IP, a part of professional services group Gateley.
Described by one respondent as a “broken funding model”, the sector’s lack of funding and difficulty securing much-needed investment capital, particularly outside of the South East, are two of the most urgent issues facing the university spinout sector.
Respondents also noted a lack of access to the senior management and professional services outside of the ‘Golden…
AMSBIO announce a new range of Synthetic Nanodiscs that enable preparation of multi-pass transmembrane proteins in their active form, revolutionizing the future of membrane protein research and drug development. Membrane Proteins account for more than 60% of all FDA-approved drug targets and 90% of antibody-based drug targets. Many traditional sample preparation methods struggle with challenges in obtaining water-soluble and bioactive forms of multi-pass transmembrane proteins.
Commonly, detergent has been widely used to produce multi-pass transmembrane proteins…
Recent top global hires for large-cap, mid-cap, and public companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech in the second half of 2024.CEO/ C-suite/ BoardCEO, Medtech (publicly listed), APACCEO, Life science tools (publicly listed), NordicsPresident Life Sciences, Specialty chemicals (large-cap), UK & IrelandChief Financial Officer Biotech (publicly listed), USChief Financial Officer, Biopharma/ drug delivery (publicly listed), UK & IrelandChief of Staff , Biopharma (publicly listed), EuropeChair, Mental health pharma (publicly listed…